CD19/BCMA Targeted CAR T-Cells is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase II drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CD19/BCMA Targeted CAR T-Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CD19/BCMA Targeted CAR T-Cells overview

Gene therapy is under development for the treatment of refractory systemic lupus erythematosus, refractory scleroderma, Sjogren's syndrome, relapsed and refractory B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin's lymphoma and multiple myeloma, refractory POEMS syndrome, amyloidosis, autoimmune hemolytic anemia, and vasculitis. It is administered through intravenous route. The therapeutic candidate comprises of T-cells which are genetically engineered to express chimeric antigen receptor, which targets cells expressing B lymphocyte antigen CD19 and BCMA.

For a complete picture of CD19/BCMA Targeted CAR T-Cells’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.